

A Trio Study Showing Novel Gene Mutation In LAMB3 Causing Junctional Epidermolysis Bullosa [Intermediate/ Severe]

Shaile Bandla ^{1,*}

¹BGCI - Genetic Counselor Asian Institute of Fetal Medicine And Reproductive Genetics -AIFMRG Trident Arafath Arcade, 10, Banjara Hills, Hyderabad, Telangana.

Abstract

Case Report

Open Access &

Peer-Reviewed Article

Corresponding author:

Shaile Bandla,BGCI - Genetic Counselor Asian Institute of Fetal Medicine And Reproductive Genetics -AIFMRG Trident Arafath Arcade, 10, Banjara Hills, Hyderabad, Telangana.

Keywords:

Junctional Epidermolysis Bullosa, Skin blistering, Trio-exome sequencing, LAMB3, Trio study, Autosomal recessive.

Received: June 29, 2023

Accepted: December 30, 2023

Published: February 01, 2024 Academic Editor:

Minoo Rassoulzadegan, University of Nice Sophia Antipolis, Genetic Laboratory of Normal and Pathological Development (Center of Biochemistry U616 INSERM) Nice.

Citation:

Shaile Bandla (2024) A Trio Study Showing Novel Gene Mutation In LAMB3 Causing Junctional Epidermolysis Bullosa (Intermediate/ Severe). Journal of Hereditary disease - 1 (1):1-4.

Background: Junctional epidermolysis bullosa (JEB) is a type of Epidermolysis Bullosa, a group of genetic conditions that cause the skin to be very fragile and to blister easily. It is categorized into: the Herlitz type and the Non-Herlitz type. JEB is inherited in an autosomal recessive pattern. Most common genetic mutations associated are LAMB3, COL17A1, or LAMC2, and LAMA3 genes.

Case presentation: This study reports a consanguineous couple, carriers for pathogenic variant LAMB3 gene, with an affected child with a homozygous mutation in the LAMB3 gene causing Herlitz type of Junctional epidermolysis Bullosa/ Non-Herlitz type of junctional epidermolysis bullosa. Furthermore, prenatal diagnosis for the Gravida also showed the same pathogenic variant.

Conclusion: For autosomal recessive genetic conditions, it is advisable to perform a Trio whole-exome sequencing or next-generation sequencing to detect the genes associated with the disease. Depending on the type of variants involved prenatal diagnosis for the next pregnancy and treatment or management (if available) options can be offered/discussed.

Introduction

Junctional epidermolysis bullosa (JEB) is a group of heritable mechanobullous diseases characterised by blistering skin or tissue separation at the lamina lucida. This blistering could be due to little or no trauma. (1,2) EB affects the epithelial lining of the organs and is often termed the "butterfly children" as the skin of the younger individuals is said to be as fragile as a butterfly's wings. Worldwide, about 50 in 1 million live births are diagnosed with Epidermolysis bullosa (EB), out of these 92% are Epidermolysis bullosa simplex (EBS), 5% are Dystrophic epidermolysis bullosa (DEB), 1% is JEB and the rest 2% remains unknown. Incidence in India is estimated to be 54 per million live births (according to National Epidermolysis bullosa Registry) (3). JEB is categorized into two different types: Severe JEB(earlier known as Helitz JEB) and Intermediate JEB (earlier known as Non-Herlitz). The H-JEB variant is characterized by the early demise of the individuals affected usually within the first year of life with severe blistering of the skin over the large regions of the body, it could also affect the mucous membranes, such as the moist lining of the mouth and the digestive tract. On the other hand, nH-JEB shows milder phenotypic symptoms with lifelong

©2024 Shaile Bandla. This is an open access article distributed under the terms of the Creative

Commons Attribution License, which permits unrestricted use, distribution, and build upon your work non-commercially.



blistering with a normal life span. (4) As per OMIM three major genes LAMA3, LAMB3, and LAMC2 that encode the subunit polypeptides of laminin-5 are associated with JEB. Out of which LAMB3 accounts for about 80% of all the laminin 5 mutations. (5) JEB represents a group of skin diseases that basically follows an autosomal recessive pattern of inheritance, in which the fetus or the children affected would be born to an obligate carrier parent who doesn't show any phenotypes of the disease. (6)

The present study reports a boy child with a homozygous mutation in the LAMB3 gene causing Herlitz type of Junctional epidermolysis Bullosa/ Non-Herlitz type of junctional epidermolysis bullosa.

Case Description

A one-month-old boy born to a consanguineous couple presented with clinical indications of skin blistering and excoriation of the skin since birth. He is suspected to be affected with epidermolysis bullosa and has been evaluated for pathogenic variations. Henceforth, the index case was evaluated for whole-exome sequencing (WES) to identify the molecular and genetic basis of suspected genetic conditions. Selective capture and sequencing of the protein-coding regions of the genome/genes are performed. DNA extracted from blood was used to perform targeted gene capture using an exome capture kit. The libraries were sequenced to mean >80-100X coverage on Illumina sequencing platform. GATK best practices framework for identification of variants in the sample using Sentieon (v201808.07) was followed. (7)

The WES analysis showed a homozygous four-base pair duplication in exon 18 of the LAMB3 gene (chr1:g.209618515dupAGCA; Depth: 150x) resulting in a frameshift and premature truncation of the protein 17 amino acids downstream to codon 950 (p.Ser950AlafsTer17; ENST00000391911.5) was detected. This variant in the LAMB3 gene was not reported earlier in the 1000 genomes, gnomAD, and the internal databases. However, based on the above evidence this LAMB3 variation is classified as a pathogenic variant.

Going forward parental segregation was performed for the carrier status of pathogenic variants in the LAMB3 gene by Next generation sequencing (NGS). The targeted analysis revealed both the parents to be carriers of a pathogenic variant in the LAMB3 gene (p.Ser950AlafsTer17). However, the p.Ser950AlafsTer17 variant has not been reported in the 1000 genomes database and has a minor allele frequency of 0.006% in the internal database. Later on prenatal diagnosis was done for the fetus to evaluate for the same gene mutation. The fetus also presented with the pathogenic variant in the LAMB3 gene.

Discussion

Intermediate junctional epidermolysis bullosa 1A (OMIM#226650) and Severe junctional epidermolysis bullosa 1B (OMIM#226700) are caused by homozygous or compound heterozygous mutations in the LAMB3 gene (OMIM*150310). Intermediate junctional epidermolysis bullosa 1A (JEB1A) is a blistering disease of the skin and mucous membranes. Generalised trauma-induced blistering occurs from birth. Blistering is less severe than in severe JEB, usually without the tendency for developing chronic granulation tissue. The plane of skin cleavage is through the lamina lucida of the cutaneous basement membrane zone. Nail dystrophy or loss and dental enamel defects are present. Scarring or non scarring alopecia and diffuse hair loss may occur. Blistering does not affect the lifespan of affected individuals. Severe junctional epidermolysis bullosa 1B (JEB1B) is a skin blistering





disorder characterised by extreme fragility of the skin and epithelia of various extracutaneous tissues. Blisters and erosions are present at birth. Blister formation occurs within the dermal-epidermal basement membrane zone. (8,9)

The LAMA3, LAMB3, and LAMC2 genes each provide instructions for making one part (subunit) of a protein called laminin 332. Laminins are a family of network-forming trimeric proteins that are significant constituents of the basal lamina, an extracellular matrix layer of the basement membrane. Henceforth any mutations in these genes would be associated with the defective or non-functional version of the protein causing JEB. (10)

As per the study by Aoi Nakano et., al, we see mutations primarily found in the 3 chain of the laminin 5, the LAMB3 gene is associated with the HEB. They studied the LAMB3 gene in about 22 families out of which 8 novel mutations were identified. Six out of 8 have created a downstream PTC (premature termination codon), and the other two showed an effect in the intron-exon borders potentially resulting in aberrant splicing. (15)

As per the study by Aoi Nakano et al., 54 mutations were identified in a cohort of 24 patients, 22 of them novel. Mutations were identified in all three laminin 5 genes, with the majority in LAMB3. The common hotspot of LAMB3 gene, R365X is seen in 14 of 36 LAMB3 gene mutations. Thirteen of 15 Herlitz JEB patients were homozygous or compound heterozygotes for PTC mutations, while in eight of 12 non-Herlitz JEB patients a PTC mutation was combined with a missense or splicing mutation. The other four of non-HJEB showed compound heterozygous for PTC mutations. (4)

In this study a Whole Exome sequencing (ES) was performed initially for the affected child who showed a homozygous four-base pair duplication in exon 18 of the LAMB3 gene and later targeted analysis performed in both the parents revealed a heterozygoius mutation in gene LAMB3 which is associated with Epidermolysis bullosa. The variant is identified to be novel as per the 1000 genome database and was not reported earlier.

Conclusion

This case report emphaisszes on the importance of parental segregation and Trio ES, as it helps in aiding parental counseling and decision making in many cases. We have demonstrated that using medical trio ES followed by a targeted panel for prenatal diagnosis allows detection of genetic conditions. Further which this helps in early detection and the management if available.

References

- Pulkkinen L, Meneguzzi G, McGrath JA, Xu Y, Blanchet-Bardon C, Ortonne JP, Christiano AM, Uitto J. Predominance of the recurrent mutation R635X in the LAMB3 gene in European patients with Herlitz junctional epidermolysis bullosa has implications for mutation detection strategy. J Invest Dermatol. 1997 Aug;109(2):232-7. doi: 10.1111/1523-1747.ep12319752. PMID: 9242513.
- Laimer, M., Lanschuetzer, C. M., Diem, A., & Bauer, J. W. (2010). Herlitz Junctional Epidermolysis Bullosa. Dermatologic Clinics, 28(1), 55–60. doi:10.1016/j.det.2009.10.006
- Prasad AN. Epidermolysis bullosae. Med J Armed Forces India. 2011 Apr;67(2):165-6. doi: 10.1016/S0377-1237(11)60024-5. Epub 2011 Jul 21. PMID: 27365791; PMCID: PMC4920676.
- 4. Nakano A, Chao SC, Pulkkinen L, Murrell D, Bruckner-Tuderman L, Pfendner E, Uitto J. Laminin



5 mutations in junctional epidermolysis bullosa: molecular basis of Herlitz vs. non-Herlitz phenotypes. Hum Genet. 2002 Jan;110(1):41-51. doi: 10.1007/s00439-001-0630-1. Epub 2001 Nov 13. PMID: 11810295.

- 5. https://www.omim.org/entry/150310
- Yancey KB, Hintner H. Non-Herlitz Junctional Epidermolysis Bullosa. Dermatologic Clinics. 2010 Jan;28(1):67-77. doi: 10.1016/j.det.2009.10.008
- 7. Freed D. et al., The Sentieon Genomics Tools-A fast and accurate solution to variant calling from next-generation sequence data. BioRxiv:115717, 2017.
- 8. https://www.omim.org/
- 9. https://www.ncbi.nlm.nih.gov/books/NBK1125/
- Poulter JA, El-Sayed W, Shore RC, Kirkham J, Inglehearn CF, Mighell AJ. Whole-exome sequencing, without prior linkage, identifies a mutation in LAMB3 as a cause of dominant hypoplastic amelogenesis imperfecta. Eur J Hum Genet. 2014 Jan;22(1):132-5. doi: 10.1038/ ejhg.2013.76. Epub 2013 May 1. PMID: 23632796; PMCID: PMC3865405.
- Mühle C, Jiang QJ, Charlesworth A, Bruckner-Tuderman L, Meneguzzi G, Schneider H. Novel and recurrent mutations in the laminin-5 genes causing lethal junctional epidermolysis bullosa: molecular basis and clinical course of Herlitz disease. Hum Genet. 2005 Jan;116(1-2):33-42. doi: 10.1007/s00439-004-1210-y. Epub 2004 Nov 5. PMID: 15538630.
- MUTATION-BASED PRENATAL DIAGNOSIS OF HERLITZ JUNCTIONAL EPIDERMOLYSIS BULLOSA. Prenatal Diagnosis, 17(4), 343–354. doi:10.1002/(sici)1097-0223 (199704)17:4<343::aid-pd73>3.0.co;2-7
- Kivirikko S, McGrath JA, Pulkkinen L, Uitto J, Christiano AM. Mutational hotspots in the LAMB3 gene in the lethal (Herlitz) type of junctional epidermolysis bullosa. Hum Mol Genet. 1996 Feb;5(2):231-7. doi: 10.1093/hmg/5.2.231. PMID: 8824879
- Sawamura D, Nakano H, Matsuzaki Y. Overview of epidermolysis bullosa. J Dermatol. 2010 Mar;37(3):214-9. doi: 10.1111/j.1346-8138.2009.00800.x. PMID: 20507384.
- Nakano A, Pfendner E, Hashimoto I, Uitto J. Herlitz junctional epidermolysis bullosa: novel and recurrent mutations in the LAMB3 gene and the population carrier frequency. J Invest Dermatol. 2000 Sep;115(3):493-8. doi: 10.1046/j.1523-1747.2000.00086.x. PMID: 11023379.

